



WE SHED LIGHT ON HEALTH

Detecting Infectious Diseases Instantly

Applying AI to smartphone images to identify disease in seconds - a patented, app-based software solution

Leading the Digital Health Paradigm Shift

Corporate Presentation

June 2025



Disclaimer

This corporate presentation of Light AI Inc. (the “Company”) and the information contained herein (the “Presentation”) is for informational purposes and is not an offer to sell or solicitation of an offer to buy securities of the Company and may not be relied upon in connection with the purchase or sale of securities. Recipients of this Presentation who are considering acquiring securities of the Company are referred to the public filings made by the Company with Canadian securities regulatory authorities, which are available under the Company’s SEDAR+ profile at www.sedarplus.ca. Information disclosed in this Presentation is current as of June 1, 2025, except as otherwise provided herein, and the Company does not undertake or agree to update this Presentation after the date hereof. This Presentation contains forward-looking statements with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “potential” and similar expressions.

Forward-looking statements contained in this Presentation and other forward-looking statements are based on management of the Company’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Forward-looking statements contained in this Presentation may include, but are not limited to statements with respect to: the Company’s intentions, plans and future actions; the business and future activities of the Company and anticipated developments in the operations of the Company; the performance of the Company’s business and operations; the length of time required to obtain permits, certifications and approvals; the Company’s expected reliance on key management personnel, advisors and consultants; expectations regarding trends in the healthcare industry; results and expectation concerning various partnerships, strategic alliances, projects and marketing strategies of the Company; and the economy generally. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and

actual results may differ materially from those in the forward-looking statements. Readers are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements based on certain risk factors including: the Company has limited operating history, which makes it difficult to evaluate the Company’s business prospects; the Company’s financial position and results of operations may differ materially from expectations; the management of the Company has limited experience managing a publicly-traded company; the Company expects to incur future losses and may never generate revenues; the Company may be unable to generate revenues or establish a subscription-based revenue model; the Company expects to require additional capital to support its business; the Company may never achieve profitability; the Company’s dependent on senior management team and key employees; the Company’s market opportunity and cost saving estimates are subject to significant uncertainty which may prove to be inaccurate; the Company may face growth-related risks; the Company could incur material losses relating to cyber-attacks or other information security breaches in the future; the risks associated with operating in a complex healthcare and technology regulatory and legal environment subject to a wide variety of laws and regulations, including those relating to provision of healthcare, consumer products, product liability and consumer protection; those relating to negligence; those relating to the manner in which the Company advertises, markets and sells products and services; labour and employment laws, including wage and hour laws; tax laws or interpretations thereof; data protection and privacy laws and regulations; the Company may face competition in its industry; the Company may be unable to adequately protect its proprietary and intellectual property rights; the Company’s reliance on obtaining and maintain regulatory approval in jurisdictions where its products or technologies are being researched, developed or commercialized; unfavorable global economic and political conditions could adversely affect the Company’s business, financial condition or results of operations; and other risks.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking statements contained in this Presentation or in certain of the other documents on file with Canadian securities regulatory authorities, which are available on the Company’s SEDAR+ profile at www.sedarplus.ca. The Company and its directors, officers and employees each disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, readers should not place undue

reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Market & Industry Data

This presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

Trademarks

This presentation includes certain trademarks that are protected under applicable intellectual property laws and are the property of the Company. Solely for convenience, these trademarks may appear without the ® or TM symbol, but such references are not intended to indicate, in anyway, that the Company will not assert its rights to these trademarks to the fullest extent under applicable law. This presentation also contains trademarks of third parties which are the property of their respective owners. The use or display of these third parties’ trademarks is not intended to, and does not imply, a relationship with the Company, or an endorsement or sponsorship by or of the Company.

U.S. Securities Law

This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States, unless an exemption from such registration is available, information concerning the assets and operations of the Company included in this Presentation has been prepared in accordance with Canadian standards and is not comparable in all respects to similar information for United States companies.

No securities regulatory authority has expressed an opinion about these securities and it is an offense to claim otherwise.

Leading the Digital Health Paradigm Shift

Patented AI Platform to Detect Infectious Diseases by analyzing Smartphone Images in Seconds



- Accurate
- Quick
- Non-invasive
- Cost efficient



- Consumer Wellness App
- Medical Professional App



- Regulatory**
- Health Canada
 - FDA
- Commercial**
- TC4A



- North America
- Lower and Middle Income Countries (LMIC)
- Europe / Australia

AI MEDICAL CONDITION DETECTION SOLUTION

- AI Platform detection of Strep A, Covid, Conjunctivitis and other medical conditions
- Developed over ten years with 13 industry research partners
- Strong patent portfolio

SIMPLE TO USE WITH FAST RESULTS

- UI friendly smartphone software app with AI image analysis ~45 seconds with diagnostic assessment
- No swabs or labs required — just a smartphone with instant screening results

MARKET OPPORTUNITY

- Leveraging massive global smartphone footprint to manage a global infectious disease and over prescription of antibiotics problem
- Professional medical devices in urgent care environments and hospitals

GO TO MARKETS PATHS

- Consumer oriented Wellness App available in Q3 2025
- Medical Professional App upon regulatory approval process with Health Canada and FDA
- Lower middle income countries (LMIC) commencing with Africa through partnership with TC4A

EXPERIENCED LEADERSHIP

- Peter Whitehead, Founder and CEO, invented the VELScope, an oral cancer screening device used globally in over 50M oral health examinations by over 10,000 dental clinics
- Leadership Team: Senior roles at Johnson & Johnson, Medtronic, Bristol Meyers Squibb, CDC and WHO

FINANCIAL

- Over CDN\$20 million investment over ten years with commercialization commencing in Q3 2025
- CDN\$11.9 million cash at March 31, 2025

Leading the Digital Health Paradigm Shift

Patented AI Platform to Detect Infectious Diseases by analyzing Smartphone Images in Seconds

As **reliable**
as traditional
test but
infinitely
faster and
more
accessible

The Problem: Trillion Dollar Crisis

- 600 million people infected by Strep A annually* killing as many as malaria**
- Trillion dollar economic damages from infectious diseases and due to misdiagnoses
- Global issue due to inappropriate use of antibiotics***
- Hospitals are drowning, antibiotics are failing, and millions lack access to basic health screening assessments

The Solution: Your Phone, Your Lifeline

- Light AI's patented platform uses AI to analyze throat images captured by your smartphone
- No extra hardware, no lab visits - just a quick scan and results in seconds
- 97% accuracy and 100% negative predictive value
- Plans to expand to COVID-19, Conjunctivitis and other medical conditions - turning your phone into a one-stop health hub



Light AI is riding two trends – **Smartphones and AI** – as they reshape healthcare




* <https://www.nature.com/articles/s41541-023-00646-6>

**<https://www.who.int/news-room/fact-sheets/detail/malaria>

*** Source: WHO named Antibiotic resistance as one top 10 Global Threats -<https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>

Leading the Digital Health Paradigm Shift

Existing Medical Ecosystem Time Consuming, Expensive, Inaccurate and Inefficient




Light AI → Immediate (On demand)

Antibiotic Misuse

10/10 have indication 6/10 receive antibiotics




Only 2 or 3 out of 10 need antibiotics*



* Shulman, S. T., Bisno, A. L., Clegg, H. W., Gerber, M. A., Kaplan, E. L., Lee, G., Martin, J. M., & Van Beneden, C. (2012). Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 55(10), 1279–1282. <https://doi.org/10.1093/cid/cis847>.
Barnett, M. L., & Linder, J. A. (2014). Antibiotic prescribing to adults with sore throat in the United States, 1997-2010. JAMA internal medicine, 174(1), 138–140. <https://doi.org/10.1001/jamainternmed.2013.11673>.

Leading the Digital Health Paradigm Shift

How it works: Identifies Infection within Seconds



Contact Healthcare Provider

Patient and healthcare provider meet over a telemedicine session - Symptoms are captured

Scan Session Initiated

Patient is prompted to scan their throat. Light AI technology automatically identifies biomarkers to analyze

Scan Analysis

Light AI immediately analyzes the scan data and returns results within seconds

On-Demand

Decision support that is immediately accessible, real time, inexpensive, non-invasive, pain free and accurate

Leading the Digital Health Paradigm Shift

Addressing Major Unmet Needs for Strep A and other Infectious Diseases

Major
Unmet
Needs for
Strep A
and other
Infectious
Diseases

NEED FOR URGENCY Strep A requires timely test results due to the potential health implications and the urgent need for treatment

INACCURATE RESULTS Doctor unable to identify Strep A through a visual assessment unlike other conditions such as skin lesions

PATIENT INCONVENIENCE Approx. 20% tests due to a bacterial infection with most doctor visits unnecessary and could be avoided with digital health screening

BEYOND STREP A Consistent impact with COVID-19, Conjunctivitis (Pink Eye) and other medical conditions


STREP A HIGH PATIENT VOLUME Very few conditions have the global reach of Strep A, infecting more than 600 million people

COSTLY INFRASTRUCTURE Common tests like a throat swab require expensive lab capabilities not available in many countries

Expansion for COVID-19, Conjunctivitis (Pink Eye) and other Medical Conditions

An Iteratively Improving AI Model

Multiple Pre-Regulatory Validation Studies



Leading the Digital Health Paradigm Shift

Robust Patent Portfolio

Patent US11369318B2

Image processing of streptococcal infection in pharyngitis subjects

United States
(June 2022)

Patent EP3864669

Image processing of streptococcal infection in pharyngitis subjects

European Union
(Dec 2024)

Patent US11602312B2

Image processing of streptococcal infection in pharyngitis subjects

United States
(March 2023)

Patent US12148150

Infection Detection Using Image Data Analysis

United States
(November 2024)


Patent 2019357949

Image processing of streptococcal infection in pharyngitis subjects

Australia
(April 2020)

Patented a method to diagnose disease
that uses AI algorithms to process
images obtained with cameras
(Including Smartphones)

Anticipated Milestones



Experienced Leadership

Management



Peter Whitehead
CEO & Founder



- 24 years experience in healthcare innovation
- Inventor of VELScope, a market leading oral cancer imaging tool
- Founder of multiple AI/Machine Learning companies & patents



Anthony Schaller
President & CTO


- Over 30 years of senior technology leadership roles, inclusive of the MP3 audio format creation, Ticketmaster and Match.com
- Senior advisor for private equity firm with over \$60B assets under management




Thomas Scarnecchia,
COO



- 30 years as a technology executive & consultant
- Former CIO and VP, Johnson & Johnson R&D
- Expertise in building data science and computational science teams




George Reznik
CFO & Corporate Secretary



- Over 25 years as CFO, COO and Corporate Secretary to five high growth public technology companies
- Former Deloitte Corporate Finance Valuation practice leader

Board Members




Steve Semmelmayer
Chairman of the Board

- 37 year veteran of the Dental Industry
- Former CEO, Denmat Holdings & Discus Dental
- Former CEO, LED Medical Diagnostics



Hugh Cleland
Board Member

- Co-founder & Portfolio Manager of Roadmap Capital
- BA from Harvard University, CFA Designation (2001)
- Awarded the "Opportunities Strategy Hedge Fund Award" for the Northern Rivers Innovation Fund in 2006.



Mark Attanasio
Board Member

- CEO ATTA Elevators Corp. & Owner of Nocera Investment Corp.
- Specialist in Canadian Venture Capital
- Former CEO Eight Capital & Dundee Capital Markets




Emmanuel Blin
Board Member




- CEO & Founder TC4A, a global digital healthcare platform
- Former Chief Strategy Officer Bristol Myers Squibb

Advisory Committee



Yu Zhao



- President of Bridging Consulting LLC, a boutique regulatory firm dedicated to servicing AI startups and medical device companies.
- 16 years at Medtronic, including as Director and Interim VP of Regulatory Affairs



Raymond Ng



- University of British Columbia, Director of Data Science Institute
- Ph.D, Computer Science ML Leader



David Bell



- Public health and internal physician, previously coordinated malaria diagnostics at WHO
- Programme Head of Malaria & Acute Febrile Disease at Foundation for Innovative New Diagnostics



David Talan



- UCLA Emergency Department MD, Infectious Disease
- Principle investigator for the CDC's national sentinel network in the United States (EMERGnEcy ID NET)

Extensive
Health,
Medical and
Technology
industry
Expensive

Financial and Capitalization Table

Financial Position at March 31, 2025

Cash:	CDN\$11.9M
Adjusted Working Capital:	CND\$12.6M
Total Assets:	CDN\$15.0M
Debt:	Nil

Capitalization at March 31, 2025

Shares Outstanding:	118,121,835
Warrants Outstanding:	24,741,291
<i>(weighted average CDN\$0.63)</i>	
Options Outstanding:	12,686,945
Deferred Stock Units Outstanding:	<u>1,750,000</u>
Fully Diluted Shares Outstanding:	<u>157,300,071</u>

Leading the Digital Health Paradigm Shift

Competitive Advantage

Accurate
Quick
Cost efficient
Impactful



Multiple Applications

Consumer Wellness
Medical Professional



Regulatory Framework

Health Canada
FDA



Expanding Solutions

Strep A
COVID-19
Conjunctivitis
Other Medical Conditions



Massive Global Market Opportunity





Thank you

Contact: investors@light.ai